Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

ClinicalTrials.gov ID

NCT07676565

Lead Sponsor

Indiana UniversityOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

300Estimated

Last Update Posted

Jun 30, 2026Actual

Start Date

Mar 24, 2026Actual

Primary Completion Date

Apr 2028Estimated

Completion Date

Apr 2028Estimated

Official Title

Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study

Brief Summary

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

• Type 1 Diabetes

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Adults ≥18 years of age
• Clinical diagnosis of T1D
• GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
• Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
• Willing and able to provide informed consent

Exclusion Criteria:

• No exclusion criteria other than those not meeting inclusion criteria above

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Indiana UniversityOTHER

Collaborators

Jaeb Center for Health ResearchOTHER

sabeena.usman@emory.edu404-251-8959

evelyn.guevara@northwestern.edu312-908-9002

loehrin1@hfhs.org313-916-3906

sophie.baum@mssm.edu212-241-4301

• GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

  NCT06630585

  RecruitingInterventionalPhase 3Updated Jan 26, 2026
• ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes

  NCT04235504

  CompletedInterventionalNot ApplicableUpdated Mar 27, 2023
• DreaMed Advisor Pro System in Subjects With Type 1 Diabetes Treated With MDI Therapy

  NCT04043260

  CompletedInterventionalNot ApplicableUpdated Aug 17, 2021
• Discovery Diabetes

  NCT07116434

  RecruitingInterventionalNot ApplicableUpdated Dec 23, 2025
• A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

  NCT02139943

  CompletedInterventionalPhase 2Updated Jul 18, 2016
• Efficacy and Safety of Frequently Modified Intensive Insulin

  NCT01014832

  CompletedInterventionalNot ApplicableUpdated Nov 17, 2009